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Raft associationncy virus type 1 (HIV-1) matrix (MA) domain is involved in both early and late
events of the viral life cycle. Simultaneousmutation of critical serine residues inMAhas been shownpreviously
to dramatically reduce phosphorylation of MA. However, the role of phosphorylation in viral replication
remains unclear. Viruses harboring serine to alanine substitutions at positions 9, 67, 72, and 77 are severely
impaired in their ability to infect target cells. In addition, the serinemutant viruses are defective in their ability
to fuse with target cell membranes. Interestingly, both the fusion defect and the infectivity defect can be
rescued by truncation of the long cytoplasmic tail of gp41 envelope protein (gp41CT). Sucrose density gradient
analysis also reveals that thesemutant viruses have reduced levels of gp120 envelope protein incorporated into
the virions as compared towild type virus. Truncation of the gp41CT rescues the envelope incorporation defect.
Herewe propose amodel inwhichmutation of speciﬁc serine residues preventsMA interactionwith lipid rafts
during HIV-1 assembly and thereby impairs recruitment of envelope to the sites of viral budding.
© 2008 Elsevier Inc. All rights reserved.IntroductionHuman immunodeﬁciency virus type 1 (HIV-1) matrix domain
(MA) is the 17 kD N-terminal cleavage product of the viral precursor
protein Pr55Gag by the viral protease (PR). PR cleavage of Pr55Gag also
yields the p24 capsid (CA), p2 spacer peptide 1, p9 nucleocapsid (NC),
p1 spacer peptide 2, and p6 domains (Wills and Craven, 1991). Our
current understanding of MA structure is based on NMR and crystal-
lographic studies (Hill et al., 1996; Massiah et al., 1996). It is
myristylated at the N-terminus (Bryant and Ratner, 1990), and it is
composed of 5 alpha-helices and a short helical stretch that form a
globular core, capped by a mixed beta-sheet. It is thought that MA
forms trimers that result in a lattice with 3-fold symmetry (Hill et al.,
1996), although a recent report suggests that MA actually forms a
hexameric lattice on membranes (Alfadhli et al., 2007). Oligomeriza-
tion creates a central hole into which, it is hypothesized, the
cytoplasmic tail of the gp41 envelope protein is inserted (Hill et al.,
1996).
MA is involved in multiple steps of the HIV-1 replication cycle
(Freed, 1998). MA is thought to have a role in viral entry by regulating
fusion with target cell membranes and uncoating of the viral core
(Gallay et al., 1995; Murakami et al., 2004; Wyma et al., 2004). MA has
been shown to be a component of both the viral reverse transcription
and the pre-integration complexes (PIC). Two proposed nucleart. Louis, MO 63110, USA. Fax: +1
l rights reserved.localization sequences in MA may aid in nuclear import of the PIC
(Bukrinskyet al.,1993;Haffar et al., 2000).MAhas also been implicated
in the export of viral RNA from the nucleus (Dupont et al., 1999).
In addition to its involvement in early replication events, MA, in
the context of Pr55Gag, plays a signiﬁcant role in late replication events
pertaining to viral assembly. The N-myristylation domain in MA is
responsible for targeting Pr55Gag to the plasma membrane and
multivesicular bodies (Bryant and Ratner, 1990; Ono and Freed,
1999, 2004; Spearman et al., 1997; Spearman et al., 1994). MA is then
thought to interact with lipid raft-associated phosphatidylinositol-
(4,5)-bisphosphate (PIP2) (Ono and Freed, 2004). The interaction with
PIP2 induces a “myristyl-switch” in MA, exposing the myristic acid
moiety, thereby allowing Pr55Gag to be speciﬁcally anchored to lipid
raft domains (Scarlatta and Carter, 2003; Spearman et al., 1997; Tang
et al., 2004; Zhou and Resh, 1996). Raft association has been
hypothesized to be important for the oligomerization of Pr55Gag
(Ono et al., 2007). MA, once at the site of budding, recruits viral
envelope (Env) to the newly forming virion via an interactionwith the
transmembrane (gp41) subunit of Env (Bhattacharya et al., 2006).
Several lines of evidence suggest an interaction between MA and
gp41, speciﬁcally with the long cytoplasmic tail of gp41 (gp41CT). Co-
expression of Env with Pr55Gag focuses budding exclusively at the
basolateral surface of polarized epithelial cells (Dorfman et al., 1994;
Owens et al., 1991). Several different mutations in MA block Env
incorporation into virus particles (Freed and Martin, 1995, 1996;
Murakami and Freed, 2000a, 2000b; Wyma et al., 2000; Yu et al.,
1992). This block is overcome by a C-terminal (CT) deletion (CTD) of
gp41 (Freed and Martin, 1995; Mammano et al., 1995). Expression of
Fig. 2. MA Ser mutant viruses are defective in virus–cell fusion not cell–cell fusion. (A)
Virus-dependent cell fusion assay was performedwithWT, andmutant 4S, 9S, and L12E
virus particles added to a 1:1 mixture of U87.CD4.CCR5.GFP cells expressing T7
polymerase or carrying the β-galactosidase gene under the regulation of the T7
promoter. The background level of mismatched Env/coreceptor was subtracted. (B)
Envelope-dependent cell–cell fusion assay. Proviral clones dEnv, WT, 4S, or 9S were
expressed in BSC40 cells with the β-galactosidase gene under the regulation of the T7
promoter. These cells were mixed with U87.CD4.CCR5.GFP cells expressing T7
polymerase, and fusion measured by β-galactosidase activity. Bars represent standard
deviations.
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pathway (Egan et al., 1996). Detergent-resistant interactions between
gp41 and Pr55Gag in virus particles depend on the gp41CT (Bhatta-
charya et al., 2004, 2006). Additionally, there is biochemical evidence
for a direct interaction of Pr55Gag with gp41CT in cell-free studies
(Cosson, 1996), although it has been proposed that a host-cell derived
bridging molecule is required to mediate the interaction (Blot et al.,
2003; Lopez-Verges et al., 2006).
Herewe further deﬁne the steps in the HIV-1 life cycle at which the
simultaneous mutation of speciﬁc serine residues, previously shown
to be critical for phosphorylation of the MA protein, impairs
replication of the mutant viruses (Kaushik and Ratner, 2004). Initially,
it was suggested that mutation of these residues in MA inhibited HIV-
1 at a post-entry step without affecting assembly of the virions
(Kaushik and Ratner, 2004). However, the data presented in this study
demonstrate that the mutated virions have an entry defect, speciﬁ-
cally at the step of viral fusion. Density gradient analysis reveals that
the fusion defect is, in large part, due to inhibition of proper envelope
incorporation into the mutant virions.
Results
Serine mutations
The MA domain of HIV-1 strain NL4-3 harbors ten serine residues,
the majority of which are conserved across HIV-1 clades. Serines (Ser)
at positions 6, 72, 77, and 129 are also conserved in HIV-2 and simian
immunodeﬁciency virus (SIV). Our previous work characterizing Ser
to alanine (Ala) substitutions in MA identiﬁed serines 9, 67, 72, and 77Fig. 1. HIV-1 matrix serine mutations. (A) The four critical serine residues at positions 9,
67, 72, and 77 are shown schematically in bold lettering in relation to other known
functional domains in MA, as well as the other serine residues in MA. The N-terminal
myristylation site (N-Myr), nuclear export signal (NES), and nuclear localization
sequences (NLS) are denoted in addition to the labeled functional domains. (B)
Molecular model of HIV-1 MA illustrating the locations of the four critical serine
residues. The orientation of the MAmolecule is such that the membrane-binding face of
MA is in the foreground, with the myristyl group protruding towards the viewer. The
molecular model of MA was generated using coordinates from Hill et al (1996) and
PyMol software (DeLano Scientiﬁc LLC.).as critical for infection (Kaushik and Ratner, 2004). Simultaneous
mutation of the four critical Ser residues (4S) or nine of the ten Ser in
MA (9S) excluding Ser 6, which is important for myristylation of MA,
led to a 95% decrease in phosphorylation of MA and a 90% reduction of
viral infectivity (Kaushik and Ratner, 2004). The ten MA Ser residues
are shown schematically in relation to other known functional
domains in MA (Fig. 1A). The locations of the four critical Ser residues
are presented on a three-dimensional model of MA (Fig. 1B).
Mutant viruses are defective in virus-dependent fusion, not cell–cell
fusion
In order to identify the mechanism by which the 4S and 9S
mutations led to a decrease in infectivity, we ﬁrst examined the ability
of mutant viruses to induce fusion with target cells. Fusion of wild
type (WT), 4S, and 9S was measured using a quantitative virus-
dependent fusion assay as described in Materials and methods
(Pontow et al., 2004). A virus, which harbors a leucine to glutamic
acid change in MA at position 12 (L12E) and has been shown to be
defective in packaging full-length envelope (Freed and Martin, 1996),
was used as a negative control. The 4S HIV-1 mutant virus
demonstrated 20% fusion activity relative to the parental isolate. The
9S HIV-1 mutant virus maintained only 10% of WT fusion levels while
L12E exhibited 5% of WT fusion levels (Fig. 2A). These results closely
mirror the results from the infectivity assays for these mutants as
previously described (Kaushik and Ratner, 2004).
It is possible that the 4S and 9S mutations in MA alter the ability of
viral envelope to induce fusion, which would explain the results of the
virus-dependent fusion assay. We used an envelope-dependent cell–
cell fusion assay to evaluate envelope protein function. Transfection of
a proviral clone lacking an env gene resulted in no detectable fusion
activity (Fig. 2B). In contrast, the envelope-dependent fusion activity
induced by the 4S and 9S mutant proviruses was not signiﬁcantly
different from that induced by the WT proviral clone. These ﬁndings
indicate that there is no intrinsic defect in fusion activity of Env in
transfected cells.
Fig. 3. Viral particle morphology is unaffected by serine mutations. Transmission electron microscopic analysis of (A) WT, (B) 4S, and (C) 9S virus particles expressed from transfected
293T cells. The bar represents 164 nm. Sizes of WT, 4S, and 9S particles were measured as 131±5.0 nm, 144±17 nm, and 134±19 nm, respectively. Arrows indicate representative
mature virions in each ﬁeld.
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Transmission electron microscopy was performed on 293T cells
expressing WT or mutant proviral genomes, as described in Materials
and methods. Each sample had similar numbers of virus particles, of
appropriate size, and primarily exhibited a mature morphology
typiﬁed by a condensed core (Fig. 3). No differences in budding
were seen, with virus particle formation at the plasma membrane.
MLV envelope overcomes 4S infectivity defect
Previous studies showed that the defect in virus infectivity could
be overcome with virus particles pseudotyped with the vesicular
stomatitis virus (VSV) glycoprotein (Kaushik and Ratner, 2004).
However, VSV-G promotes virus entry through a pH-dependent
mechanism, whereas HIV-1 and amphotropic murine leukemia virus
(MLV) enter cells through a pH-independent mechanism (McClure et
al., 1990). In order to determine if the defect in infectivity was speciﬁc
for the HIV-1 envelope, virus particles were pseudotyped with the
amphotropic murine leukemia virus (MLV) envelope (Fig. 4). In this
case, infectivity was determined on a CD4+ HeLa cell line that also
contained a luciferase reporter gene. Efﬁcient pseudotype formation
was demonstrated by the high levels of infection with MLV-
pseudotyped particles that lack HIV-1 envelope (Env−). Moreover,
MLV pseudotyped virus also overcame the defect associated with
L12E. The MLV pseudotype of wild type HIV resulted in a non-
statistically signiﬁcant increase in infectivity (p= .12). In contrast, MLV
pseudotype overcame the defect associated with the 4S mutation
(p b .02), resulting in infection levels similar to that of MLV
pseudotyped wild type HIV (p= .34).
Truncation of gp41CT rescues 4S and 9S infectivity and fusion defects
There is a functional interaction between the long cytoplasmic
tail of gp41 (gp41CT) and MA. Multiple studies have demonstrated
that this interaction plays an important regulatory role in both
assembly and entry, speciﬁcally in fusion, of HIV-1. In order toFig. 4. MLV envelope overcomes the fusion defect of MA 4S Ser mutant. Virus was
produced in 293T transfected with each proviral clone with or without the addition of
the MLV envelope expression plasmid. The resultant virus was titered on JC53 cells, and
mean levels, and standard deviations are shown for 6 replicates of the experiment.understand how this interaction may inﬂuence the phenotypes of
the 4S and 9S mutants, we produced mutant proviral clones with a
truncated gp41CT. This was accomplished by the introduction of a
stop codon into the gp41 coding sequence such that the C-terminal
144aa of gp41 are not translated. We then examined the effects of
this truncation (gp41 CTD) on viral infectivity (Fig. 5A) and fusion
(Fig. 5B).
Infectivitywasmeasuredby incubatingequivalent amounts of virus,
as determined by p24 ELISA, with MAGI-5 (HeLa β-galactosidase+,
CD4+, CCR5+) cells. Relative infectivity for the mutant viruses was
determined by counting numbers of blue-stained cells per well and
reporting them as a percentage of WT infectivity levels. As reported
previously, with full-length gp41, 4S showed 20% of WT level of
infection, and 9S had 10% of WT activity (Fig. 5A). As a control, mutant
L12E was included, which produced particles defective in their ability
to incorporate full length envelope, and only 5% of WT infection
activity was obtained (Fig. 5A) (Freed and Martin, 1996). In contrast,
with the gp41 CTD mutant, 4S and WT showed very similar levels of
infection. Mutant L12E was almost as infectious as WT virus in
association with the gp41 CTD mutation, as previously described
(Freed andMartin,1996). The 9SMAmutant showed a 4-fold increased
level of infection with CTD, although it did not recover full infection
activity. Interestingly, virus containing WT MA in the context of the
gp41 CTD was not as infectious as WT virus with full-length gp41CT.
Infectivity was also examined over multiple replication cycles in
JC53 (HeLa CD4 cells). Consistent with the results obtained in single
cycle infection assays (Fig. 5A), mutants 4S and 9S also showed
defective replication over the course of a 13 day assay (Fig. 6).
Moreover, the CTD mutant overcame the defect seen in 4S.Fig. 5. C-terminal TM deletion overcomes the fusion defect of MA Ser mutants. Virus
from WT, 4S, 9S, and L12E clones with or without a gp41 CTD was examined for (A)
infection of MAGI-R5 cells and (B) virus-dependent fusion activity.
Fig. 6. C-terminal TM deletion overcomes replication defect of MA Ser mutant over
multiple replication cycles. Virus from WT, 4S, 9S, WT CTD and 9S CTD was used to
infect JC53 cells, which were split 1:2.5 on days 5 and 9. Cells were lysed at each time
point and luciferase assays performed.
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using the virus-dependent fusion assay described above. With the
full-length gp41, mutant L12E showed background levels of fusion
activity (Figs. 1A and 5B), and fusion induced by 4S and 9S was
attenuated. With gp41 CTD, MA mutants 4S and L12E exhibited fusionFig. 7. Levels of envelope incorporated into Ser mutant virions are reduced. Metabolically-la
resuspended and centrifuged through 20–60% sucrose density gradients. (A) Amount of label
fractions were consistently ∼1.13–1.14 g/ml, suggesting that they contain mature viral partic
used to quantify gp120 and p24 bands for each immunoprecipitated fraction in panel B. Lev
gp120 to p24 in each peak fraction. The experiments shown are representative ﬁgures and reﬂ
ratios between WT and 4S were highly signiﬁcant (2 tailed t test p b .001).activity similar to that of WT virus. Mutant 9S combined with gp41
CTD partially recovered fusion activity.
Levels of envelope incorporated into Ser mutant virions are reduced
In order to fully assess whether assembly of mutant HIV-1 virions
was affected by the serine mutations in MA, we used sucrose density
gradient analysis to examine mature particles. For this purpose, we
focused on 4S, since 4S CTD completely reconstituted fusion activity.
293T cells were transfected with 10 μg of proviral DNA. Cells were
metabolically labeled 1 day post-transfection and virus-containing
supernatant was harvested 2 days later. The virus samples were then
pelleted through a sucrose cushion, resuspended in OptiMEM and
layered on top of a 20–60% sucrose density gradient. The radioactivity
levels and densities of the gradient fractions are shown graphically in
Fig. 7A. Mature particles have been shown to have a density of
approximately 1.14 g/ml–1.16 g/ml (Tang et al., 2003). Peak fractions
with densities between 1.12 g/ml and 1.16 g/ml were collected and
immunoprecipitated with pooled AIDS patient sera. The immunopre-
cipitated fractions were resolved by SDS-PAGE (Fig. 7B). As previously
reported (Kaushik and Ratner, 2004), Gag synthesis and processing
appears to be unaffected by the 4S and 9S mutations. However, in
contrast to our earlier published work, densitometry comparing the
gp120 (Env) to p24 (Gag) ratios of WT virions and those of the serine
MA mutant virions (Fig. 7C) revealed that the levels of envelope
incorporated into mature 4S were reduced by 70–80%. L12E and dENV
viruses were used as controls for envelope incorporation in these
experiments. Although levels of gp120 incorporation seen here in
L12E expressing cells compared to WT virions and in 5 independent
experiments (10–25%) are higher than previously reported, the earlier
manuscripts did not include sucrose gradient analyses (Freed and
Martin, 1995, 1996).beled virus fromWT, 4S, L12E, and dEnv clones was pelleted through a sucrose cushion,
ed protein in each fractionwas measured using a scintillation counter. Densities of peak
les. (B) Immunoprecipitation of peak fractions with AIDS pt sera. (C) Densitometry was
els of envelope incorporation, relative to WT, were measured by calculating the ratio of
ect the data from at least three independent experiments. The differences in gp120/p24
Fig. 9. Association of Pr55Gag with detergent resistant membranes. Lysates from 293T
cells transfectedwith proviral DNAwere incubated on ice either in the (A) absence or (B)
and (C) presence of cold 0.25% Triton X-100 and subsequently subjected to equilibrium
ﬂotation centrifugation. Ten fractions were collected from the top of the gradient,
precipitated and resolved by SDS PAGE. Gag in each fraction was detected by western
blotting with polyclonal anti-p24 antibody. Detergent resistant membrane (DRM)
fractions and detergent soluble (DS) fractions are shown. The experiments shown are
representative ﬁgures and reﬂect the data from two independent experiments.
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We have demonstrated that truncation of the gp41CT partially
rescues the infectivity and fusion defects induced by the 4S and 9S
mutations. Sucrose density gradient analysis of mature viral particles
produced from 293T cells expressingWTor 4S, either in the context of
full-length gp41CT or with truncated gp41 tails (CTD), reveals that the
phenotype rescue by CTD is largely due to a restoration of envelope to
the virions (Fig. 8).
Mutation of critical serine residues in MA abrogates association of
Pr55Gag with rafts
Several reports propose that the association of Pr55Gag with lipid
rafts is important for proper viral assembly and envelope incorpora-
tion. In order to determine if simultaneous mutation of the four
critical serine residues in MA affects the ability of Pr55Gag to associate
with lipid rafts, we performed membrane ﬂotation assays, either in
the absence or presence of 0.25% Triton X-100, on 293T cells
transfected with proviral clones. The amount of Pr55Gag associated
with detergent resistant membrane fractions was analyzed by
western blotting with anti-p24 polyclonal antisera for WT and 4S
viruses (Figs. 9A–C). Antibodies to the raft-associated marker
calveolin-1 (Cav-1) and the non-raft associated transferrin receptor
(Tfr) were used as controls to deﬁne the detergent-resistant
membrane fractions (not shown). Although, no difference was seen
in the ability of Pr55Gag harboring the 4S mutation to associate with
detergent soluble membranes (not shown), the ability of this mutantFig. 8. Rescue of envelope incorporation defect by truncation of gp41CT. Virus from 4S
and 4S CTD clones were analyzed by sucrose density gradients. (A) Immunoprecipita-
tion of peak fractions with AIDS pt sera is shown. (B) Levels of envelope incorporated
into mutant virions, as measured by gp120:p24 ratios, are also shown.to associate with detergent resistant membranes was severely
reduced.
The results of this experiment were validated and further
quantiﬁed by examining levels of p24 by antigen ELISA assays. A
total of 39% of wild type Gag protein was found in DRM fractions 3–5
(Fig. 10, top). In contrast, only 19% and 16% of 4S and 9S Gag proteins,Fig. 10. Quantitative analysis of Gas association with detergent resistant membranes.
Gag p24 antigen ELISA was used for quantiﬁcation of sucrose gradient fractions, using
lysates from cells transfected with WT, 4S, or 9S virus with or without an MLV
pseudotype, as well as WT CTD and 4S-CTD. Each experiment was repeated on at least
two independent occasions with similar results, and are not based on the same
gradients shown in Fig. 9.
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the defect associated with the 4S mutant, the effect of MLV Env on
DRM association was also analyzed. Interestingly, in the presence of
the MLV Env, both wild type and 4S Gag was exclusively associated
with detergent-soluble membranes (Fig. 10 middle). We also analyzed
the effect of the CTD Env mutation which also corrected the defect.
Once again, this mutation also resulted in a lower proportion of Gag
protein in DRM fractions (8% and 3% for WT CTD and 4S CTD,
respectively, Fig. 10, bottom)
Discussion
In this report, we further determine the nature of the infectivity
defect demonstrated by viruses harboring mutations of critical serine
residues. Initially, it was thought that the combined mutation of
serines at positions 9, 67, 72, and 77 to alanine inhibited HIV-1
replication at a post-entry step in the viral life cycle. While the current
study does not rule out possible post-entry deﬁciencies, our results
indicate that the mutated viruses are, in fact, deﬁcient in their ability
to enter target cells (Fig. 2).
Our previous study showed that levels of viral protein synthesis
and processing by the 4S and 9S mutants were comparable to those of
wild type virus, suggesting that the combined serine mutations did
not affect assembly (Kaushik and Ratner, 2004). In addition, ratios of
gp120 envelope to p24 as measured in virions pelleted through a
sucrose cushion were equivalent between WT, 4S, and 9S virus
preparations. However, careful analysis of mature viral particles
isolated by centrifugation through linear sucrose density gradients,
suggests that the serine mutations affect viral entry by reducing the
efﬁciency of envelope incorporation into viral particles, or the stability
of gp120 on virus particles (Fig. 7). The 4S virus had only 20–30% of
wild type levels of viral envelope incorporated into mature particles.
The 9S virus demonstrated an even greater deﬁciency of virus-
associated envelope (not shown). The envelope incorporation values
correlate well with the infectivity and fusion data for the serine
mutants and likely explains the entry deﬁcits induced bymutations of
the critical serine residues in MA.
The infectivity defect of 4S was overcome with VSV-G or MLV Env
pseudotyped particles, whereas the defect in 9S was only partially
overcome by VSV-G pseudotyped particles (Fig. 4) (Kaushik and
Ratner, 2004). In our previous work, we failed to show that MLV Env
could overcome the infectivity defect of 4S, but that study did not
control for levels ofMLV Env expression (Kaushik and Ratner, 2004). In
the current study, levels of MLV Env were sufﬁcient to overcome the
infectivity defect of Env−, L12E, as well as 4S HIV-1. These ﬁndings
further support the hypothesis that a defect in HIV envelope
incorporation were responsible for a defect in the infection associated
with Ser mutant virus.
Numerous studies have demonstrated a functional interaction
between MA and envelope, speciﬁcally the gp41CT, in both assembly
and entry. Evidence for interactions between the cytoplasmic tails (CT)
of envelope transmembrane (TM) subunits and structural matrix
proteins is supported by ﬁndings from other retroviruses. For
example, the CT portions of TM of murine leukemia virus and
Mason–Pﬁzermonkey virus envelopes are cleaved by the viral PR after
virus release, and this cleavage event is required for Env fusion activity
(Brody et al., 1994; Rein et al., 1994). Moreover, truncation of the TM CT
of visna virus, HIV, SIV, and HTLV-1 activates fusion activity (Dubay et
al., 1992; Freed and Martin, 1996; Kim et al., 2003; Rein et al., 1994;
Spies and Compans, 1994; Zeilfelder and Bosch, 2001). This type of
regulatory interaction between MA and TM domains appears to
extend to other, non-retroviral families as well. Studies of measles,
inﬂuenza, rabies and respiratory syncytial viruses have also shown
that matrix proteins interact with envelope CT, inﬂuence envelope
incorporation and regulate fusion (Cathomen et al., 1998; Henderson
et al., 2002; Mebatsion et al., 1999; Nayak et al., 2004).Two studies demonstrate that uncleaved Gag protein blocks Env-
mediated fusion (Murakami et al., 2004; Wyma et al., 2004). Neither
levels of virion-associated Env, Env-mediated attachment to CD4+ T
cells, nor initiation of early fusion events by Env are affected by
uncleaved Gag (Murakami et al., 2004). These studies suggest that
interactions between MA, in the context of Pr55Gag, and gp41CT may
regulate one of several steps in the fusion reaction. Together, these
ﬁndings led us to consider whether altered interactions between MA
and Env may be responsible for the phenotypes observed with the 4S
and 9S mutants.
In order to test the hypothesis that altered gp41–MA interac-
tions are responsible for the 4S and 9S mutant phenotypes, we
truncated the C-terminal 144 amino acids of the gp41CT in the
context of wild type viruses and those harboring the 4S and 9S
mutations in MA. Truncation of the gp41CT (CTD) has been shown
to rescue envelope incorporation defects induced by mutations in
the MA basic domain and overcome the fusion defect induced by
uncleaved Gag. This CTD modiﬁcation rescued infectivity and fusion
for the 4S virus, and partially rescued infectivity and fusion for the
9S virus (Figs. 5, 6). The partial rescue phenotype exhibited by 9S
CTD may reﬂect an additional block to replication, perhaps at a
post-entry step.
Sucrose density gradient analysis of 4S CTD virus revealed that
gp120 envelope was restored to the mutant virions (Fig. 8). In fact, we
saw increases in gp120:p24 ratios to levels signiﬁcantly above those of
WT when gp41CT was truncated in the context of WT, 4S and 9S MA
(data not shown). Interestingly, despite increasing the relative amount
of envelope incorporated into virions, truncation of gp41CT in context
of WT MA led to reduced infectivity compared to WT virus (Fig. 5).
This would suggest that the MA–gp41CT interaction regulates
envelope incorporation to ensure an optimal ratio of envelope to
Gag protein in the virions. Exceeding this ratio does not increase the
ﬁtness of the virus.
The current literature supports the notion that Gag actively
packages envelope into the budding virions during assembly by
recruiting the Env trimers to lipid rafts in the plasma membrane from
which immature particles bud (Bhattacharya et al., 2004). While this
seems to be the preferred mechanism for homologous HIV-1
envelope, which does not target to lipid rafts in the absence of Gag,
to be packaged into HIV-1 virions, other membrane proteins, such as
heterologous pseudotyped envelopes appear to be packaged through
a passive mechanism (Landau et al., 1991; Spector et al., 1990). Studies
of HIV-1 and SIV support the passive packaging model for truncated
forms of envelope glycoproteins and other membrane glycoproteins
(Guern and Levy, 1992; Johnston et al., 1993; Salzwedel et al., 1993;
Sauter et al., 1996). Passive packaging of membrane proteins into HIV-
1 virions appears to be an unregulated process and this appears to be
the mechanism by which HIV-1 envelope proteins with truncated
gp41CT are incorporated into virions.
The gp41 CT is known to have several regulatory elements as well
as being the domain for envelope interaction with MA/Gag. Highly
conserved tyrosine-based YXXL and di-leucine endocytosis motifs
reside in the gp41CT, and mutation of these motifs overcomes the
effects of MA mutations associated with envelope incorporation
defects (Byland et al., 2007; Egan et al., 1996; Ohno et al., 1997; West
et al., 2002). Several intracellular trafﬁcking molecules modulate the
functional interaction between gp41 and MA (Batonick et al., 2005;
Byland et al., 2007; Dong et al., 2005; Egan et al., 1996; Noble et al.,
2006; Ohno et al., 1997; Blot et al., 2003; Lopez-Verges et al., 2006).
An alternative hypothesis arises from evidence suggesting that
mutations in MA can adversely affect the stability of the gp41–
gp120 interaction (Davis et al., 2006). Mutation of the leucine at
residue 49 to an aspartic acid (L49D) resulted in virions that had
normal incorporation of gp41, but reduced gp120. Truncation of
gp41CT rescued the L49D phenotype and restored gp120 to virions. It
is possible that 4S and 9S mutations could destabilize the non-
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contribute to the reduced levels of gp120 found in the mutant
virions. However, there was no evidence for gp120 instability on the
surface of transfected cells (Fig 2b).
Recent studies have highlighted the requirement of detergent-
resistant membranes or lipid rafts in Gag multimerization and Env
incorporation. Pulse–chase experiments demonstrate that HIV-1
Pr55Gag associates with detergent resistant membranes (DRM) soon
after membrane binding (Halwani et al., 2003; Ono and Freed, 1999,
2001). The interaction of Pr55Gag with DRM is thought to be mediated
by the N-terminalMAdomain. Asmentioned above, MA interacts with
PI(4,5)P2, which has been postulated to facilitate Pr55Gag association
with rafts (Ono and Freed, 2004; Saad et al., 2006; Shkriabai et al.,
2006). Depletion of cholesterol from producer cell membranes
signiﬁcantly reduces the production of HIV-1 viral particles and
impairs the oligomerization of Pr55Gag (Ono et al., 2007). Interestingly,
Pr55Gag is required for Env associationwith lipid rafts, suggesting that
Pr55Gag actively recruits Env trimers to the sites of viral assembly and
budding (Bhattacharya et al., 2006). Presumably, regulation of
envelope incorporation is mediated by the interaction between MA
and gp41CTat lipid rafts. Disruption of this interaction or disruption of
Pr55Gag association with lipid rafts may lead to improper assembly of
virions.
Membrane ﬂotation in the presence of cold 0.25% Triton X-100
indicates that the 4S mutation in MA inhibits the association of
Pr55Gag with detergent resistant membranes (Figs. 9, 10), potentially
explaining the envelope incorporation defect exhibited by the
mutation. This appears to contradict computational models which
predict that the serine phosphorylation of MA actually weakens
interactions with membranes (Murray et al., 2005). Reduction of MA
phosphorylation by the 4S mutation may inhibit association with raft
lipids directly, but it is also possible that the 4S mutation affects the
interaction with another molecule, such as PIP2, which is responsible
for targeting Gag to raft domains (Ono and Freed, 2004; Saad et al.,
2006). However, mutations that mimic phosphorylation of the matrix
protein do not enhance PIP2 binding, although this study investigated
only single not multiple Ser mutations (Saad et al., 2007).
The role of lipid rafts in HIV envelope incorporation into particles is
further emphasized by the ﬁndings that co-expression of heterologous
viral glycoproteins such as VSV-G and MLV Env overcome the defect
associated with the 4S mutant. VSV-G is localized throughout the
plasma membrane rather than speciﬁcally with detergent-resistant
rafts, and presumably overcomes the MA mutation by facilitating
infectious virus particle budding at non-raft domains (Oomens et al.,
2006; Pickl et al., 2001). MLV Env, is predominantly but not exclusively
associated with rafts, and also overcomes the effects of the 4S
mutation (Beer et al., 2005). The ﬁndings in Fig. 10 argue that non-raft
associated MLV Env may be responsible for the phenotypic rescue of
4S.
It is also important to consider other effects of the 4S and 9S
mutations. We have discussed the importance of the interaction
between gp41CTandMA in regulation of viral assembly and entry. The
4S and 9S mutations may inhibit a direct interaction between the two
proteins. We propose that abrogating the phosphorylation of MA
inhibits its ability to target to the appropriate micro-domains of the
plasma membrane and consequently impairs its ability to recruit Env
to the sites of viral assembly. Alternatively, the mutations may disrupt
raft association through effects unrelated to their effects on phos-
phorylation. Truncation of the gp41CT appears to release envelope
from regulation by HIV-1 MA and allow a reversion to a passive
packaging mechanism. Future studies will examine the molecular
mechanism by which mutation of the critical serine residues in MA
inhibits raft association and envelope incorporation. Further under-
standing of MA interactions with gp41CT and membrane sites of viral
assembly may provide new insight for the rational design of
therapeutic interventions against HIV-1.Materials and methods
Plasmids, cell culture, and transfection
The 4S and 9Smutationswere generated in p134, an NL4-3 proviral
clone backbone including gag derived from X4-strain HXB2 and env
derived from R5-strain YU2, as described previously (Kaushik and
Ratner, 2004). In both 4S and 9S, Ser residues 9, 67, 72, and 77 were
replaced by Ala residues. In 9S, Ser residue 54 was replaced by Ala, and
Ser residues 38, 111, 126, and 129 by Asn residues. Two incidental
conservative mutations are also present in 9S at positions 102 and 125
substituting Glu for Asp and Asn for His residues, which are common
polymorphisms present in all HIV-1 clades (Leitner et al., 2007).
Envelope glycoprotein gp41 C-terminal deletion (CTD) mutants were
generated by introducing a stop codon to produce TM lacking the C-
terminal 144 amino acids (Freed and Martin, 1995; Murakami et al.,
2004; Wyma et al., 2004). The BssHII–SphI gag fragment of gp41-CTD
was substituted with the gag cassettes encoding serine mutants.
Proviral clones were transfected into 293T cells with TransIT-LT1
(Mirus) according to manufacturer protocol. 293T and BSC40 cells
were maintained in DMEM supplemented with 10% Fetal-Clone III
(Hyclone), 4 mM L-glutamine, and penicillin–streptomycin. MAGI-5
reporter cells (Pirounaki et al., 2000) were maintained in supple-
mented DMEM with puromycin, hygromycin, and G418. U87 (CD4+,
R5+) were maintained in DMEM supplemented with 10% Fetal-Clone
III, 4 mM L-glutamine, penicillin–streptomycin, puromycin and G418.
Western blotting and immunoprecipitation
Western blotting for p24 and Pr55Gag was performedwith anti-p24
polyclonal rabbit serum. Anti-p17 polyclonal rabbit serumwas used to
detect MA. HIV-1 proteins were immunoprecipitated with pooled
HIV-1 patient sera. Anti-caveolin-1 (Santa Cruz Biotechnologies) and
anti-transferrin receptor 1 (Zymed) antibodies were used as controls
in detergent-resistant membrane assays.
Infectivity assay
MAGI-5 cell lines (HeLa β-galactosidase+, CD4+, CCR5+) or JC53 cell
lines (HeLa β-galactosidase+, Luc+, CD4+, CCR5+) were plated in a 96
well plate at a density of 104 cells per well. The cells were then
infected with 25 ng of virus, as determined by p24 ELISA (Beckman-
Coulter, Fullerton, CA), of virus in triplicate. Virus was removed from
MAGI-5 cells 40 h post-infection and the cells were then ﬁxed with
PBS containing 1% formaldehyde (Sigma, St. Louis, MO) and 0.2%
glutaraldehyde (Sigma, St. Louis, MO) for 5 min at room temperature.
Cells were washed in PBS and stained with X-gal (Calbiochem San
Diego, CA) for 35 to 55 min at 37 °C. Cells were thenwashed again and
the number of blue cells per well was counted. For short-term JC53
cell assays, luciferase activity was determined after 40 h . Statistics
were performed by an unpaired 2-tailed t test. For long-term JC53 cell
assays, cells were split 1:2.5 at days 5 and 9.
Virus-dependent fusion assay
The virus-dependent fusion assay was performed as described
previously (Pontow et al., 2004). U87 glioma cells expressing CD4 and
a CCR5-GFP fusion protein, U87.CD4.CCR5.GFP cells were infected with
recombinant vaccinia virus with β-galactosidase under the control of
the T7 promoter (vCB21R), or recombinant vaccinia virus expressing
T7 polymerase (vPT7-3). Cells were infected overnight, harvested by
trypsin treatment, resuspended in HBSS with 3% fetal calf serum, and
mixed (1:1) in triplicate wells of a 96-well plate, and then equivalent
amounts of HIV-1 and 20 μg/ml DEAE-dextran were added. Fusion
reactions were incubated for 3 h at 37 °C. Fusion was stopped by the
addition of NP-40 to a ﬁnal concentration of 1% and β-galactosidase
240 A.K. Bhatia et al. / Virology 384 (2009) 233–241activity was determined using chlorophenol red-β-D-galactopyrano-
side (Calbiochem, San Diego, CA) as substrate, and reading the
absorbance at 579 nm.
Envelope-dependent fusion assay
WT and mutant proviral clones were transfected into BSC40 cells.
After 24 h , these cells were infected with vPT7-3. An equal number of
U87.CD4.CCR5.GFP cells were infected with vCB21R. Cells were
cultured overnight, harvested by trypsin treatment, washed and
mixed in triplicate wells of a 96-well plate. Cell–cell fusion reactions
were incubated for 3 h at 37 °C, and β-galactosidase activity in cell
lysates determined.
Transmission electron microscopy
293T cells were transfected with proviral clones. Two days post-
transfection, cells were harvested, ﬁxed in 2.5% glutaraldehyde in
0.1 M sodium cacodylate buffer, and post-ﬁxed with 1% osmium
tetroxide at 4 °C. Dehydration with graded ethanol was performed.
The samples were embedded, sectioned, and examined with a Zeiss
EM 900 electron microscope.
HIV-1 sucrose gradient analysis
293T cells plated in 100 mm dishes were transfected with 10 μg of
proviral DNAusing TransIT (Mirus) transfection reagent as described in
the manufacturer's protocol. Transfection media was removed 1 day
following transfection and the cells were then metabolically labeled
with 200 μl of 35-S Translabel (MPbio) in cys(−)/met(−) DMEM
(Washington University Tissue Culture Center). Supernatants contain-
ing radiolabeled virus were then harvested 48–60 h later. The viral
supernatants were subsequently cleared of cellular debris by centri-
fugation for 5 min at low speed. Viruses were pelleted through a 20%
sucrose cushion via ultracentrifugation at 45,000 rpm for 45 min in an
SW55Ti rotor (Beckman). The pelleted virus was then resuspended in
700 μl of OptiMEM (Invitrogen) and gently layered at the top of a 16ml
20–60% sucrose gradient. The gradient was then centrifuged at
26,000 rpm in an SW28 rotor (Beckman) for 24 h. 1 ml fractions
were collected from the top of the gradient. The gradient fractions
were analyzed for refractive index using a refractometer (Fisher
Scientiﬁc Co.) and measured for radioactivity using a scintillation
counter (Beckman-Coulter). The density of each fraction was calcu-
lated using the formula ρ=2.6496 η−2.5323, where ρ is density (g/ml)
and η is the refractive index (Forshey et al., 2002; Tang et al., 2003).
Peak fractions with densities greater than 1.12 g/l but less than 1.16 g/l
were then immunoprecipitated overnight with pooled AIDS patient
sera at 1:100 dilution. Immunoprecipitated samples were then
resolved by electrophoresis through a 15% SDS-PAGE gel. The gel was
subsequently ﬁxed, dried, and exposed to a phosphoimager screen for
24 h. The screen was then analyzed by the STORM phosphoimager
system and quantiﬁed using MacQuant imaging software.
Detergent resistant membrane studies
The association of retroviral Gag proteins with detergent resistant
membrane fractions was analyzed as described previously (Feng et al.,
2003). Brieﬂy, 293T cells transfected with proviral clones were
harvested in ice-cold PBS 48 h post-transfection. Cells were lysed in
1 ml of hypotonic lysis buffer (10 mM Tris–Cl pH 7.5, 1 mM MgCl2) on
ice for 10 min and subsequently dounce homogenized for 45 strokes.
Lysates were cleared of nuclear material by centrifugation for 10 min
at 2000× g at 4 °C. The post-nuclear lysate was then adjusted to
150 mM NaCl, split into 400 μl fractions, and kept on ice. 10% Triton X-
100 in NTE buffer (10 mM Tris–Cl, pH 7.5, 5 mM EDTA, 150 mM NaCl)
was added to one of the lysate fractions to obtain 0.25% Triton X-100and incubated for 20 min on ice. The lysate fractions were thenmixed
with 1.4 ml of 80% sucrose in NTE buffer at the bottom of a 5 ml
ultracentrifuge tube (Beckman-Coulter). 2 ml of 55% sucrose in NTE
and 1 ml of 6% sucrose in NTE were layered over the 80% sucrose–
lysate mixture. The gradients were spun for 18–24 h at 45,000 rpm in
a Beckman-Coulter SW55Ti rotor. Ten fractions of equal volume were
collected from top to bottom, precipitated with trichloroacetic acid
(Sigma) and analyzed bywestern blot using anti-p24 polyclonal rabbit
antisera. Western blotting with anti-Caveolin-1 (Invitrogen) and anti-
transferrin receptor was used to deﬁne DRM fractions. Alternatively,
p24 antigen ELISA was used to quantitate Gag levels in each gradient
fraction.
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